H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Relay Therapeutics to $19 from $33 and keeps a Buy rating on the shares post the Q3 report. The analyst redacted in the peak penetration rate for Relay’s PI3Ka programs to 15%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RLAY:
- Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference
- Relay Therapeutics reports Q3 EPS (54c), consensus (83c)
- Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
- Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
- Relay Therapeutics price target raised to $33 from $30 at H.C. Wainwright